Dataset from A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases

The purpose of the study is to develop a 20% subcutaneous immunoglobulin treatment option for
patients with primary immunodeficiency (PID) diseases.

本研究旨在开发一款适用于原发性免疫缺陷病（primary immunodeficiency, PID）患者的20%浓度皮下注射免疫球蛋白（subcutaneous immunoglobulin）治疗方案。